As prevention of distant breast cancer recurrence is the main goal of adjuvant endocrine therapy in patients with hormone receptor-positive disease, distant recurrence free-interval should in our opinion be the primary study objective of translational biomarker studies aiming at identifying patients who might benefit from additional adjuvant therapies. The gene discussed is NR4A1; the disease is breast carcinoma.